Showing 5631-5640 of 5956 results for "".
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- New Medscape Report Finds More Than One in Three Doctors are Burned Outhttps://modernod.com/news/new-medscape-report-finds-more-than-one-in-three-doctors-are-burned-out/2476292/Burnout and depression are having a significant effect on the global medical community, as demonstrated by Medscape’s Global Physicians’ Burnout and Lifestyle Comparisons report. Nearly 20,000 doctors in six countries (France,
- Eyenovia Confirms Expanded MicroProst Phase 3 Indication to Enroll Broad Patient Population for IOP Loweringhttps://modernod.com/news/eyenovia-confirms-expanded-microprost-phase-3-indication-to-enroll-broad-patient-population-for-iop-lowering/2476294/Eyenovia confirmed a broad patient population for its phase 3 MicroProst program (microdose latanoprost with Optejet delivery) for the lowering of IOP. Following discussions with the FDA, the study population will include chronic a
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)
- Topcon Healthcare Solutions and Oculo Form Global Partnershiphttps://modernod.com/news/topcon-healthcare-solutions-and-oculo-form-global-partnership/2476308/Topcon Healthcare Solutions (THS) and Oculo, a technology provider in clinical communications based out of Melbourne, Australia, have announced a new partnership that will combine the strengths of their Topcon Harmony and Oculo eye care platforms. Financial terms of the deal were not disc
- CEI Vision Partners Adds Virginia Eye Consultants as Fifth Partnerhttps://modernod.com/news/cei-vision-partners-adds-virginia-eye-consultants-as-fifth-partner/2476310/CEI Vision Partners (CVP), a portfolio company of Revelstoke Capital Partners LLC , a Denver-based private equity firm, has completed a partnership with Virginia Eye Consultants (VEC) , a premier multi-specialty ophthalmology group comprised of 17 providers that service the Norfolk, Virginia Beac